What the Purchase Price Includes

A system price covers the console, a defined set of applicators or treatment handpieces, installation and training, and whatever service arrangement is bundled with it. What it does not usually cover is the consumable cycle that follows, which is where the economics of this category are decided.

Reading a quotation therefore means separating the one-time lines from the recurring ones. The console, applicator set, training, and commissioning are capital or near-capital items; the applicator replacements, coupling media, calibration, and software licensing are recurring. A quotation that presents a single figure without distinguishing between the two makes it impossible to model cost per treatment, which is the only figure a clinic can compare against its own price list. Asking for the breakdown is the first commercially useful move in the process.

New Versus Pre-Owned Cost Bands

The two routes price different packages rather than the same machine at two figures. A new system carries a current software release and the manufacturer’s support path; a pre-owned system carries a placed platform whose scope, applicator position, and support arrangement depend on the seller.

The variable that moves value most in the pre-owned route is not the console’s age but the applicator position: how many remain, what life is left in each, and whether replacements can be obtained. That is also the item sellers most often leave vague, and vagueness in this line is what converts an attractive price into an unpriced risk.

Applicator and Consumable Cycles

Applicators on this class of platform carry a specified treatment limit, which means their cost is consumed per treatment rather than per year. That single fact is what makes the per-treatment calculation possible and simultaneously makes it necessary.

• The stated treatment cycle limit per applicator, from the manufacturer’s documentation rather than from a sales summary.
• How many cycles an average session consumes under the clinic’s protocol, since protocols vary by treatment area.
• Replacement cost per applicator, and the lead time to obtain one.
• Whether cycle tracking is enforced by the platform or managed administratively by the clinic.
• Any coupling media or single-use accessories consumed per session.

Because the console cost is fixed and the applicator cost scales with volume, the cost per treatment falls as utilization rises. That relationship is the core of the business case: a clinic that delivers few sessions on the platform carries a high per-treatment cost regardless of how favorable the purchase price looked, and a clinic with a full appointment book converts the same machine into a materially lower unit cost.

Treatment Pricing and Throughput Assumptions

Treatment pricing has to clear the per-treatment cost with enough margin to fund marketing, room time, and staff. The relationship is straightforward, but the inputs are frequently optimistic, particularly the assumption about how many treatments will be delivered in the first year.

• Market price band for the treatment in the clinic’s location, taken from local competitors rather than national averages.
• Sessions per treatment course, and how many courses a typical client completes.
• Minutes of room and practitioner time per session, at loaded cost.
• Realistic weekly volume, drawn from comparable services the clinic already delivers.
• Ramp period before the treatment line reaches steady volume.

Two assumptions deserve scepticism. A new treatment line takes time to sell, so the first months carry applicator consumption against low revenue. And throughput is limited by practitioner availability rather than by the machine, which means the platform’s theoretical capacity is rarely the constraint that matters.

Building a Payback Model

A payback model for this category is a volume question expressed as arithmetic. Fixed costs are incurred whether or not the platform runs; contribution per treatment is what the clinic keeps after consumables and delivery costs; and payback is the point at which accumulated contribution covers the capital outlay.

• Capital outlay, including the applicator set supplied and any installation costs.
• Fixed monthly cost: financing or depreciation, service, software, and insurance.
• Variable cost per treatment: applicator cycles consumed, coupling media, staff time, room time.
• Revenue per treatment at the planned price, less any package discount.
• Monthly volume assumption by month, reflecting the ramp rather than a steady figure from month one.
• Sensitivity: what payback becomes if volume lands materially below plan.

The sensitivity line converts a projection into a decision range. A purchase that still returns its cost at reduced volume is robust; one that works only at plan is a bet on demand for a treatment the clinic has not previously sold.

Verification Before Buying: Claims and Clearance

Verification protects the business case as much as it protects the patient. A platform that cannot be serviced, or whose consumable supply is uncertain, will not deliver the volume the model assumes, and the regulatory position determines what the clinic may lawfully market.

• The clearance and labeling position, and the treatments the platform’s intended use actually covers.
• Applicator authenticity and provenance, and whether replacements are available on a predictable basis.
• Whether marketing claims can be substantiated from the manufacturer’s documentation or published literature.
• Service capability independent of the original vendor, and calibration arrangements.
• Warranty and support terms in writing, with exclusions and response commitments stated.

Claims made about clinical outcomes should be assessed against the device’s cleared intended use and published evidence rather than against promotional material, and the US reference point for device status is the FDA medical device portal. Where a model’s safety history is relevant, independent alert reporting such as that published by ECRI is the usual cross-check, and evidence quality is best judged against peer-reviewed literature and the material published by professional societies including the Radiological Society of North America and the American College of Radiology.

Service, Calibration and Support Terms

Energy-delivery platforms depend on calibration to deliver the intended effect, so the service arrangement is part of the clinical proposition rather than a maintenance cost. A platform that cannot be calibrated promptly drifts out of specification, and the clinic absorbs that as inconsistent outcomes rather than as an invoice line.

• Calibration interval, method, and whether output verification is measured and recorded.
• Who performs calibration, and whether that capability exists independently of the original vendor.
• Response commitment for a fault, and the downtime the clinic should expect to absorb.
• Whether the service agreement includes applicators or treats them as a consumable purchase.
• Total cost of the agreement across the term, expressed per month and per treatment at expected volume.

Maintenance and calibration expectations should be set against recognized practice rather than agreed informally, and bodies such as AAMI publish equipment-maintenance guidance that clinical engineering functions use to define intervals and documentation. That documentation is also what supports the platform’s value at resale, because a device with a service record and a verified calibration history attracts a different buyer pool from one without.

Trade-In and Finance Options

The capital question and the transaction structure are separable, and treating them separately usually improves the outcome. Financing converts the outlay into a recurring payment and moves the comparison to total cost across the term; a trade-in applies value from an existing unit inside the purchase.

• Term length relative to the platform’s useful life, and what happens at the end of it.
• Whether the structure is treated as an asset purchase or an operating cost, and how that affects the capital plan.
• Whether the outgoing unit is traded against the purchase, and how the credit is scheduled.
• End-of-term options: purchase, extend, upgrade, or return, and the figures attached.
• Early-termination terms, and whether the agreement is assignable if the practice changes hands.

A trade-in is worth valuing before the new platform is specified, because a credit agreed after the purchase price is fixed tends to be absorbed into the negotiation rather than added to it. Where the clinic is replacing rather than adding a treatment line, the outgoing unit’s documentation — service history, applicator position, and license status — is what determines the credit, and it is easiest to assemble while the unit is still in service.

The purchase figure and the per-treatment figure answer different questions, and a clinic needs both before committing. The first is negotiated with a supplier; the second is calculated from cycle limits, session protocols, and the volume the clinic can genuinely deliver. Where the two are kept apart, the model tends to assume a throughput the appointment book cannot support, and the platform’s cost per treatment turns out higher than the price list allows for. Verification, warranty terms, and applicator supply are what keep the second calculation honest, and they are also what protect the platform’s value if it is later sold or traded. Clinics comparing a new purchase against a used unit can review the Sofwave comparison for clinics, check what a verified refurbished unit involves through pre-owned and refurbishment, and put the specification and consumable position into a quotation request before deciding.

Questions About Sofwave Investment